In recent years preclinical data suggest that addition of Epidermal Growth Factor Receptor (EGFR) inhibitors can increase the activity of the use of gemcitabine and radiation in pancreatic cancer cell lines and tumors [7, 8]. The gene discussed is EGFR; the disease is familial pancreatic carcinoma.